MD430C2 - Procedeu de obţinere a interferonelor leucocitare umane - Google Patents

Procedeu de obţinere a interferonelor leucocitare umane

Info

Publication number
MD430C2
MD430C2 MD95-0076A MD950076A MD430C2 MD 430 C2 MD430 C2 MD 430C2 MD 950076 A MD950076 A MD 950076A MD 430 C2 MD430 C2 MD 430C2
Authority
MD
Moldova
Prior art keywords
pst
pbr
leucocytar
interferone
preparation
Prior art date
Application number
MD95-0076A
Other languages
English (en)
Russian (ru)
Inventor
Van Norman Goeddel David
Pestka Sidney
Original Assignee
F.Hoffmann-La Roche Ag
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag, Genentech, Inc. filed Critical F.Hoffmann-La Roche Ag
Publication of MD430C2 publication Critical patent/MD430C2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • C12N15/71Expression systems using regulatory sequences derived from the trp-operon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Invenţia se referă la tehnologia recombinării ADN, adică la procedeele utilizate la tehnologia ADN-recombinantă şi la produsele obţinute prin aceste procedee. Tulpina bacteriilor Escherichia coli se transformă cu recombinantele din grupa pLeIF A 25, pLeIF B trp 7, pLeIF C trp 35, pLeIF D trp 11, pLeIF F trp I, pLeIF I trp 1 şi pLeIF J trp I, în continuare se cultivă transformanţii, se extrage şi se purifică interferona leucocitară.Revendicări:1
MD95-0076A 1980-07-01 1994-12-30 Procedeu de obţinere a interferonelor leucocitare umane MD430C2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16498680A 1980-07-01 1980-07-01
US18490980A 1980-09-08 1980-09-08
US20557880A 1980-11-10 1980-11-10
US06/256,204 US6610830B1 (en) 1980-07-01 1981-04-21 Microbial production of mature human leukocyte interferons

Publications (1)

Publication Number Publication Date
MD430C2 true MD430C2 (ro) 1996-06-30

Family

ID=27389083

Family Applications (1)

Application Number Title Priority Date Filing Date
MD95-0076A MD430C2 (ro) 1980-07-01 1994-12-30 Procedeu de obţinere a interferonelor leucocitare umane

Country Status (6)

Country Link
US (2) US6610830B1 (ro)
KR (1) KR860001558B1 (ro)
CA (1) CA1341583C (ro)
GE (1) GEP20074163B (ro)
MD (1) MD430C2 (ro)
ZW (1) ZW14781A1 (ro)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US7959910B2 (en) * 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
US7666995B2 (en) * 2000-11-03 2010-02-23 Pestka Biomedical Laboratories Interferons, uses and compositions related thereto
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
ATE386054T1 (de) * 2002-08-31 2008-03-15 Cj Corp Glycosylierte humane interferon alpha isoform
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1565205A4 (en) * 2002-11-18 2006-07-05 Maxygen Inc Interferon-alpha polypeptides and conjugates
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ,インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
CN101115769A (zh) * 2004-05-19 2008-01-30 马克西根公司 干扰素-α多肽和偶联物
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
EP1888633A4 (en) * 2005-05-18 2010-01-27 Maxygen Inc UNFOLDED INTERFERON ALPHA POLYPEPTIDE
MX2007014889A (es) * 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
AU2006255122B2 (en) * 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
WO2007127949A2 (en) * 2006-04-27 2007-11-08 Sko Flo Industries, Inc. Flow control valve
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
US7956161B2 (en) * 2007-04-11 2011-06-07 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2009015336A2 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2a, 이의 합성 방법 및 용도
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
AU2009268841B2 (en) 2008-07-08 2014-02-06 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
BR112013032188A2 (pt) 2011-06-23 2016-12-20 Digna Biotech Sl composição, produto e método para tratar pacientes com hepatite c crônica
PT2822575T (pt) 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
US9644015B2 (en) * 2012-03-30 2017-05-09 Biogenomics Limited Codon optimized sequence for an antiviral protein
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001929B1 (en) 1977-11-08 1989-04-19 Genentech, Inc. Plasmid for transforming bacterial host to render it capable of polypeptide expression
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
IN150740B (ro) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
ES479300A1 (es) 1979-04-04 1979-07-01 Cusi Lab Procedimiento de obtencio de &-metil, 4(2'tienil carbonilz) fenil acetato de p-acetamido fenol.
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4418149A (en) 1980-01-10 1983-11-29 President And Fellows Of Harvard College Fused hybrid gene
US4801685A (en) 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4810645A (en) 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shigekazu N. et al. Synthensin E. coli of a polypeptide with human leukocyte interferon activity. Nature, v. 284, March, 1980, p. 316-320. *

Also Published As

Publication number Publication date
ZW14781A1 (en) 1982-04-21
KR830006422A (ko) 1983-09-24
US6482613B1 (en) 2002-11-19
GEP20074163B (en) 2007-07-10
US6610830B1 (en) 2003-08-26
KR860001558B1 (ko) 1986-10-04
CA1341583C (en) 2008-11-18

Similar Documents

Publication Publication Date Title
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
EP0653940A4 (en) GLIALMITOGENIC FACTORS, THEIR PRODUCTION AND USE.
MD431C2 (ro) Procedeu de obţinere a interferonului leucocitar
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
KR970000808B1 (en) Human proapolipoprotein a-1 expression
MY101972A (en) Primate interleukin - 4
AU1348083A (en) Dna sequences, recombinant dna molecules and preparations of cholera toxin
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DK188582A (da) Bacillus-kloningsvektorer rekombinations-dna-molekyler bacillus-vaerter transformeret dermed samt fremgangsmaader til ekspressionaf fremmede dna-sekvenser og fremstilling af polypeptideer som er kodede dermed
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
ES8703490A1 (es) Un procedimiento para producir un polipeptido que tiene o contiene un polipeptido de factor de necrosis de tumor humano
DE3586697D1 (en) Aktive thymopentin-analoga.
DK54184A (da) Dna-sekvenser, rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af human (interleukin) to-lignende polypeptider
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
FI861653A7 (fi) Eristetty DNA-yhdiste, joka koodaa rekombinantti DNA isopenisilliini N-syntetaasia, sitä sisältävät vektorit ja menetelmä isopenisilliini N-syntetaasiaktiivisuuden tuottamiseksi näiden avulla
JPS615392B2 (ro)
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
GB9215232D0 (en) Vaccines
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
ATE215123T1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
ES8800353A1 (es) Procedimiento de clonacion de factor humano viii-r.
TW342413B (en) Novel toxins isolated from Bracon Hebetor
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines